Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawesi.

OBJECTIVE: This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi. METHODS: A cross-sectional study was conducted among the 79 residents of Dodolo village, who following praziquantel-mass drug administration. A-questionnaire was used to collect demographic information of the subject who participated in the study, the presence of treatment-related symptoms, and community perception. The health perception was based on the health belief model (HBM) framework. Data were analyzed using Chi-square. RESULT: The incidence of praziquantel-related adverse events was 92% (73), with the highest frequency were nausea (69%), vomit (57%), and headache (47%). The total number of treatments related to symptoms was significantly correlated with age (p 0.030). 78% (62) of participants had a supportive perceived susceptibility, 71% (56) participants had a supportive perceived severity, 63% (50) participants had supportive perceived benefits, meanwhile 58% (46) had a not supportive perceived barrier to praziquantel mass drug administration. The presence of praziquantel-related adverse events was significantly correlated with a perceived barrier of the participant to the chemopreventive program. CONCLUSION: The Dodolo community had a supportive health perception for the success of the Schistosomiasis elimination program, despite the high frequency of adverse events after praziquantel consumption.

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis.

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Four bibliographic databases and a preprint database were searched for potentially relevant articles. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 1,937 patients treated with CCP and 3,405 patients without CCP retrieved from 12 studies were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without the CCP had a 1.32 times higher risk of mortality than those treated with the CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, reduces the mortality rate among COVID-19 patients.

Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawesi

Objective: This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi. Methods: A cross-sectional study was conducted among the 79 residents of Dodolo village, who following praziquantel-mass drug administration. A-questionnaire was used to collect demographic information of the subject who participated in the study, the presence of treatment-related symptoms, and community perception. The health perception was based on the health belief model (HBM) framework. Data were analyzed using Chi-square. Result: The incidence of praziquantel-related adverse events was 92% (73), with the highest frequency were nausea (69%), vomit (57%), and headache (47%). The total number of treatments related to symptoms was significantly correlated with age (p 0.030). 78% (62) of participants had a supportive perceived susceptibility, 71% (56) participants had a supportive perceived severity, 63% (50) participants had supportive perceived benefits, meanwhile 58% (46) had a not supportive perceived barrier to praziquantel mass drug administration. The presence of praziquantel-related adverse events was significantly correlated with a perceived barrier of the participant to the chemopreventive program. Conclusion: The Dodolo community had a supportive health perception for the success of the Schistosomiasis elimination program, despite the high frequency of adverse events after praziquantel consumption. (AU)